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Carving depression at its joints? 
 
Personalization of treatments has long been an aspiration for medicine and has recently 
evolved into a sophisticated practice for the treatment of some diseases. Although in 
psychiatry treatment decisions are usually based on the individual patient and his/her needs, 
there is a lack of information about how the benefits and harms of individual 
pharmacological agents (and indeed treatments in other modalities) differ from patient to 
patient and very limited data on which to base the choice between treatment options for 
individual patients. The thoughtful paper by R. Perlis1 addresses the challenges in 
personalization of antidepressant treatment and highlights various important scientific 
questions thereof.  
Perlis suggests that available phenomenological patient-level features may be of more 
help than generally acknowledged for establishing probability of response. Whilst many 
might have sympathy with this view, history is replete with debates about the therapeutic 
utility of various subdivisions of depression, perhaps most notably the prolonged dispute 
between the Newcastle categorical2 and the Maudsley dimensional3 approach. Such 
arguments remain inconclusive.  
However, other recent work has focused on the cases of depression which have 
undiagnosed bipolar disorder and highlighted this as an area potentially important for 
personalizing treatment. The seminal paper by Angst et al4 showed that broad diagnostic 
criteria (in comparison with DSM-IV-TR criteria) identified a large number of additional 
patients with major depressive episodes who were likely manifesting depression as part of a 
bipolar disorder. These authors suggest that additionally considering family history, illness 
course and clinical status, as well as diagnostic criteria, may provide useful information for 
physicians when assessing evidence of bipolarity in patients with major depressive episodes. 
Many such patients (with major depressive episodes as part of a bipolar disorder) will be 
treated with but not respond to antidepressants. This has led to the notion being 
promulgated that all antidepressants should be, as a regulatory requirement, tested in 
bipolar major depressive episodes as well as in unipolar depression5. 
Perlis also reviews biological approaches, but the question remains: are the currently 
available putative biomarkers of antidepressant response really more robust and consistent 
tools compared to “artisanal” practice?  For example, the correlation between plasma drug 
levels and clinical response is weak and not only are drug plasma levels poorly associated 
with doses of drugs, but there is also a significant dissociation between brain and plasma 
kinetics, as demonstrated by positron emission tomography (PET) receptor occupancy 
studies6. Many factors, other than plasma levels, moderate drug action in the central 
nervous system. These factors will affect the predictive ability of pharmacogenomic 
biomarkers that are directly linked to pharmacokinetic variables, for example those which 
are genetic determinants of drug metabolism, and limit their potential contribution in 
increasing precision of pharmacotherapies.  
The development of high precision pharmacotherapies is typically driven by the 
combination of three factors: a) treatments are potentially highly efficacious if the right 
treatment is given to the right person; b) treatments are very expensive; c) treatments may 
be associated with serious adverse effects. The need for careful pre-selection of a specific 
treatment for the right patients becomes highest in those diseases in which it is most 
important to direct expensive investments to the patients identified with highest-benefit 
and lowest-risk potential. For mood disorders as a whole, there is arguably less of a 
compelling need for this kind of “precision” treatments: pharmacotherapies for depression 
are relatively affordable, compared to those for autoimmune or neoplastic diseases, and 
very serious adverse effects are rare. Thus, clinicians may end up trusting more their own 
“artisanal” judgment based on experience than not very informative evidence-based 
medicine inspired treatment protocols and guidelines. 
The integration of multimodal biomarker approaches may potentially increase precision 
but at the moment their cost and complexity is high and the utility of this approach 
unproven. New biomarker approaches (transcriptomic, proteomic, genomic and telomeric) 
may potentially change this7. However, it will be important to establish how much higher 
remission rates can be achieved with such multimodal biomarkers informing personalized 
treatment before advocating this approach. Even if this could not be translated into clinical 
practice because of cost and complexity, proof of concept would answer crucial clinical 
research questions that have remained unresolved despite the overall progress in 
neuroscience. 
Where does all of this leave us? It may be worthwhile pausing to reflect on how 
progress was achieved recently in other fields of medicine.  Although we often feel that our 
problems are unique to psychiatry, the confounding effects of heterogeneity are not 
confined to mood disorders and have been addressed in other fields of study by focussing on 
the most reliable diagnoses which are most tractable for research8. This has produced major 
advances in the understanding of genetics in Alzheimer’s disease, which have underpinned 
ongoing therapeutic research. This approach has also been shown to be practical in familial 
studies of lithium response9. Extending this approach further to mood disorders might mean 
focussing, for instance, on bipolar I disorder with a strong familial component. We could 
apply this “narrow” approach to therapeutic research in this area and combine it with the 
multimodal biomarker notions outlined above. Any relationship between biomarkers and 
therapeutic responses could then be further verified in larger clinical populations.  
What of “broad” approaches, i.e. studying a multiplicity of factors in large groups of 
heterogeneous patients? This will undoubtedly continue and may be made potentially more 
fruitful by recent developments. The recent revision of DSM introduced new ways of splicing 
major depression, including the delineation of various facets of the clinical symptomatology. 
An interesting example of the potential advantages of this development is a recent study on 
major depression with mixed features10.  
Future progress will likely come from the application of both “narrow” and “broad” 
approaches, focussed on valid and well characterized patient samples, trying, to quote 
Socrates, to “divide things again by classes, where the natural joints are”. 
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